China Is Collecting DNA From Tens of Millions of Men and Boys, Using U.S. Equipment
By Sui-Lee Wee,
The New York Times
| 06. 17. 2020
Even children are pressed into giving blood samples to build a sweeping genetic database that will add to Beijing’s growing surveillance capabilities, raising questions about abuse and privacy.
The police in China are collecting blood samples from men and boys from across the country to build a genetic map of its roughly 700 million males, giving the authorities a powerful new tool for their emerging high-tech surveillance state.
They have swept across the country since late 2017 to collect enough samples to build a vast DNA database, according to a new study published on Wednesday by the Australian Strategic Policy Institute, a research organization, based on documents also reviewed by The New York Times. With this database, the authorities would be able to track down a man’s male relatives using only that man’s blood, saliva or other genetic material.
An American company, Thermo Fisher, is helping: The Massachusetts company has sold testing kits to the Chinese police tailored to their specifications. American lawmakers have criticized Thermo Fisher for selling equipment to the Chinese authorities, but the company has defended its business.
The project is a major escalation of China’s efforts to use genetics to control its people, which had been focused on tracking ethnic minorities and...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...